Zanini Nicola, Lombardi Raffaele, Masetti Michele, Giordano Marco, Landolfo Giovanni, Jovine Elio
Department of Surgery, Maggiore Hospital, Bologna, Italy,
Updates Surg. 2015 Mar;67(1):19-25. doi: 10.1007/s13304-015-0283-6. Epub 2015 Feb 22.
The resection of liver metastases from pancreatic ductal adenocarcinoma has been discouraged because it is commonly thought that it does not improve survival. However, the role of potential prognostic factors is unclear, and universally accepted strategies have not been proposed. Between 2003 and 2014, 15 patients with isolated synchronous or metachronous metastases from pancreatic cancer underwent liver resection in our department. The role of potential prognostic factors was analyzed to predict survival. One right hepatectomy, 1 bisegmentectomy and 13 wedge resections were performed. Eleven patients underwent simultaneous pancreatic and liver resection for synchronous disease. The median overall survival (OS) was 9.1 months (95% CI 8.6-9.7). The only potential prognostic factor that significatively affected survival was the timing of metastases (metachronous vs. synchronous). Median OS in patients with metachronous disease was 11.4 months (95% CI 0-25.1) vs. 8.3 months (95% CI 6.9-9.7), p = 0.038. Surgery for liver metastases from pancreatic cancer is not suggested for most patients. If resection is considered, timing of metastatic disease could be a prognostic factor for survival after surgery.
由于人们普遍认为切除胰腺导管腺癌的肝转移灶并不能提高生存率,因此一直不鼓励进行此类手术。然而,潜在预后因素的作用尚不清楚,也尚未提出普遍接受的策略。2003年至2014年间,我科有15例孤立性同步或异时性胰腺癌肝转移患者接受了肝切除术。分析了潜在预后因素对生存的预测作用。实施了1例右半肝切除术、1例双段肝切除术和13例楔形切除术。11例患者因同步性疾病接受了胰腺和肝脏联合切除术。中位总生存期(OS)为9.1个月(95%CI 8.6-9.7)。唯一显著影响生存的潜在预后因素是转移时间(异时性与同步性)。异时性疾病患者的中位OS为11.4个月(95%CI 0-25.1),而同步性疾病患者为8.3个月(95%CI 6.9-9.7),p = 0.038。对于大多数患者,不建议对胰腺癌肝转移进行手术。如果考虑进行切除术,转移疾病的时间可能是术后生存的一个预后因素。